Literature DB >> 11732920

Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide.

B Poeggeler1, L Miravalle, M G Zagorski, T Wisniewski, Y J Chyan, Y Zhang, H Shao, T Bryant-Thomas, R Vidal, B Frangione, J Ghiso, M A Pappolla.   

Abstract

Inheritance of apoE4 is a strong risk factor for the development of late-onset sporadic Alzheimer's disease (AD). Several lines of evidence suggest that apoE4 binds to the Alzheimer Abeta protein and, under certain experimental conditions, promotes formation of beta-sheet structures and amyloid fibrils. Deposition of amyloid fibrils is a critical step in the development of AD. We report here that addition of melatonin to Abeta in the presence of apoE resulted in a potent isoform-specific inhibition of fibril formation, the extent of which was far greater than that of the inhibition produced by melatonin alone. This effect was structure-dependent and unrelated to the antioxidant properties of melatonin, since it could be reproduced neither with the structurally related indole N-acetyl-5-hydroxytryptamine nor with the antioxidants ascorbate, alpha-tocophenol, and PBN. The enhanced inhibitory effects of melatonin and apoE were lost when bovine serum albumin was substituted for apoE. In addition, Abeta in combination with apoE was highly neurotoxic (apoE4 > apoE3) to neuronal cells in culture, and this activity was also prevented by melatonin. These findings suggest that reductions in brain melatonin, which occur during aging, may contribute to a proamyloidogenic microenvironment in the aging brain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11732920     DOI: 10.1021/bi0114269

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  33 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

2.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

Review 3.  Novel therapeutics for Alzheimer's disease: an update.

Authors:  David J Bonda; Hyun-Pil Lee; Hyoung-gon Lee; Avi L Friedlich; George Perry; Xiongwei Zhu; Mark A Smith
Journal:  Curr Opin Drug Discov Devel       Date:  2010-03

Review 4.  Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology.

Authors:  Md Farhad Hossain; Md Sahab Uddin; G M Sala Uddin; Dewan Md Sumsuzzman; Md Siddiqul Islam; George E Barreto; Bijo Mathew; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2019-06-17       Impact factor: 5.590

5.  Dual role of mitochondria in producing melatonin and driving GPCR signaling to block cytochrome c release.

Authors:  Yalikun Suofu; Wei Li; Frédéric G Jean-Alphonse; Jiaoying Jia; Nicolas K Khattar; Jiatong Li; Sergei V Baranov; Daniela Leronni; Amanda C Mihalik; Yanqing He; Erika Cecon; Vanessa L Wehbi; JinHo Kim; Brianna E Heath; Oxana V Baranova; Xiaomin Wang; Matthew J Gable; Eric S Kretz; Giulietta Di Benedetto; Timothy R Lezon; Lisa M Ferrando; Timothy M Larkin; Mara Sullivan; Svitlana Yablonska; Jingjing Wang; M Beth Minnigh; Gérald Guillaumet; Franck Suzenet; R Mark Richardson; Samuel M Poloyac; Donna B Stolz; Ralf Jockers; Paula A Witt-Enderby; Diane L Carlisle; Jean-Pierre Vilardaga; Robert M Friedlander
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-05       Impact factor: 11.205

Review 6.  Role of melatonin in neurodegenerative diseases.

Authors:  V Srinivasan; S R Pandi-Perumal; G Jm Maestroni; A I Esquifino; R Hardeland; D P Cardinali
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

7.  Frontiers in Alzheimer's disease therapeutics.

Authors:  Jeremy G Stone; Gemma Casadesus; Kasia Gustaw-Rothenberg; Sandra L Siedlak; Xinglong Wang; Xiongwei Zhu; George Perry; Rudy J Castellani; Mark A Smith
Journal:  Ther Adv Chronic Dis       Date:  2011-01-01       Impact factor: 5.091

Review 8.  A Review of Melatonin, Its Receptors and Drugs.

Authors:  Mucahit Emet; Halil Ozcan; Lutfu Ozel; Muhammed Yayla; Zekai Halici; Ahmet Hacimuftuoglu
Journal:  Eurasian J Med       Date:  2016-06

Review 9.  Circadian disruption and human health: A bidirectional relationship.

Authors:  Sabra M Abbott; Roneil G Malkani; Phyllis C Zee
Journal:  Eur J Neurosci       Date:  2019-01-03       Impact factor: 3.386

Review 10.  Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases.

Authors:  Lynn Marie Trotti; Elias G Karroum
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.